Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Not Yet Recruiting Phase 2 / 3 Trials for Nivolumab (DB09035)

IndicationStatusPhase
DBCOND0113388 (Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8)Not Yet Recruiting2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT06203600Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, The PARAMMUNE TrialTreatment